# Litfulo (ritlecitinib tosylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ritlecitinib

> The FDA approved Litfulo (ritlecitinib tosylate), sponsored by PFIZER INC (PFE), on June 23, 2023 for to treat severely patchy hair loss.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Litfulo (ritlecitinib tosylate) FDA approved?

Yes. The FDA approved Litfulo (ritlecitinib tosylate), sponsored by PFIZER INC (PFE), on June 23, 2023 for to treat severely patchy hair loss. FDA novel drug approvals: "Litfulo | ritlecitinib | 6/23/2023 | To treat severely patchy hair lossDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/ritlecitinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/ritlecitinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Litfulo (ritlecitinib tosylate) |
| Codes | PF-06651600 |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | To treat severely patchy hair loss, Stable Nonsegmental Vitiligo, [Alopecia Areata](https://sec-api.dev/indications/alopecia-areata), [Hidradenitis Suppurativa](https://sec-api.dev/indications/hidradenitis-suppurativa), [Vitiligo](https://sec-api.dev/indications/vitiligo), [Chronic Spontaneous Urticaria](https://sec-api.dev/indications/chronic-spontaneous-urticaria) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 23, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat severely patchy hair loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Litfulo | ritlecitinib | 6/23/2023 | To treat severely patchy hair lossDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA215830 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230623, review_priority STANDARD; sponsor_name PFIZER; product LITFULO (RITLECITINIB TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215830%22

### February 5, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05583526 (A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-05 (ACTUAL); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05583526

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Spontaneous Urticaria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07219615

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07228390

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hidradenitis Suppurativa.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07228390

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Spontaneous Urticaria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07219615

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06163326

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06163326 (A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06163326

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06072183 (A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06072183

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06072183 (A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06072183

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06873945

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06873945 (A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-19 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06873945

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07733765

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07733765 (A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-26 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07733765

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Avtx-009 regimen 1](https://sec-api.dev/pdufa/avtx-009-regimen-1) (AVTX)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Bempikibart (adx-914)](https://sec-api.dev/pdufa/bempikibart-adx-914) (QTTB)
- [BRINSUPRI® (brensocatib)](https://sec-api.dev/pdufa/brensocatib) (INSM)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [Lou064 (blinded)](https://sec-api.dev/pdufa/lou064-blinded) (NVS)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [LY4005130](https://sec-api.dev/pdufa/ly4005130) (LLY)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide) (REGN)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)
- [Rezpegaldesleukin](https://sec-api.dev/pdufa/rezpegaldesleukin) (NKTR)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [SAR445399](https://sec-api.dev/pdufa/sar445399) (SNY)
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [Tev-53408 dose a](https://sec-api.dev/pdufa/tev-53408) (TEVA)
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart) (MRK)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Zasocitinib (dose a)](https://sec-api.dev/pdufa/zasocitinib-dose-a) (TAK)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [March 2028](https://sec-api.dev/fda-calendar/2028-03), [April 2028](https://sec-api.dev/fda-calendar/2028-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ritlecitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Litfulo (ritlecitinib tosylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ritlecitinib

```bibtex
@misc{secapidev_pdufa_ritlecitinib_20261116,
  title        = {Litfulo (ritlecitinib tosylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ritlecitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ritlecitinib_20261116","title":"Litfulo (ritlecitinib tosylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ritlecitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
